BioIntelliSense's new BioButton for 90-days of continuous wireless temperature and vital signs monitoring on a coin-sized disposable medical device
News | Wearables
Medtronic Announces Partnership with BioIntelliSense for Exclusive U.S. Distribution of Multi-Parameter Wearable for Continuous Remote Patient Monitoring from in-Hospital to Home 

August 31, 2022 — Medtronic plc, a global leader in healthcare technology, announced it has entered into a strategic ...

Home August 31, 2022
Home
Healthcare providers should promote prevention of atrial fibriliation, an abnormal heart rhythm disturbance, and early interventions among both female and male patients, say Cedars-Sinai investigators. Photo by Getty Images.
News | Atrial Fibrillation
Gender Differences and AFib: New Study Flips Conventional Wisdom

August 31, 2022 — Science has long shown that men are at greater risk for developing atrial fibrillation (AFib) than ...

Home August 31, 2022
Home
70-year-old White male patient with weight of 79.8 kg, BMI of 29.3, low cardiovascular risk factors (nonsmoker, no diabetes diagnosis, blood pressure of 120/78). Left: Axial CT image at level of L3 vertebral body. Right: Matching automated segmentation label map. Visceral fat area z score is 1.41, corresponding to the 92nd percentile. Patient experienced both subsequent myocardial infarction and stroke.
News | Computed Tomography (CT)
CT-Derived Body Composition With Deep Learning Predicts Cardiovascular Events

August 31, 2022 — According to ARRS’ American Journal of Roentgenology (AJR), fully automated and normalized body ...

Home August 31, 2022
Home
A clinician using Ultrasound Workspace from Philips
News | ESC
Philips Spotlights Integrated, Data-Driven Cardiology Solutions at ESC 2022

August 30, 2022 — Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, will showcase its latest ...

Home August 30, 2022
Home
SECURE trial presented in a Hot Line Session today at ESC Congress 2022
News | ESC
Polypill Reduces Cardiovascular Events in Heart Attack Patients Compared to Usual Care

August 30, 2022 — A pill containing aspirin and medications to lower lipids and blood pressure more effectively prevents ...

Home August 30, 2022
Home
The MOMENTUM 3 study showcases the significant survival benefits of Abbott's heart pump technology, particularly in a patient population with limited therapy options
News | ESC
New Data Show Abbott's Heartmate 3 Heart Pump Extends Life Beyond Five Years for Advanced Heart Failure Patients

August 30, 2022 — Abbott announced new late-breaking data that show its HeartMate 3 heart pump extends survival of ...

Home August 30, 2022
Home
Late-breaking data presented at ESC Congress 2022 and simultaneously published in The New England Journal of Medicine confirms implant procedure safety and defibrillation success
News | Heart Failure
FARXIGA Significantly Reduced the Risk of Cardiovascular Death or Worsening of Heart Failure in Patients with Mildly Reduced or Preserved Ejection Fraction in DELIVER Phase III Trial

August 29, 2022 — Detailed results from the DELIVER Phase III trial showed AstraZeneca’s FARXIGA (dapagliflozin) ...

Home August 29, 2022
Home
Late-breaking data presented at ESC Congress 2022 and simultaneously published in The New England Journal of Medicine confirms implant procedure safety and defibrillation success
News | Implantable Cardioverter Defibrillator (ICD)
Medtronic Extravascular ICD meets global pivotal clinical trial’s safety and effectiveness endpoints

August 29, 2022 — Medtronic plc announced that its investigational EV ICD System – a first-of-its-kind defibrillator ...

Home August 29, 2022
Home
Amarin Corporation plc announced that new REDUCE-IT data show that VASCEPA/VAZKEPA (icosapent ethyl) significantly reduced cardiovascular (CV) events in patients with a history of smoking. 
News | ESC
New REDUCE-IT Data Released at ESC Oral Presentation Session

August 29, 2022 — Amarin Corporation plc announced that new REDUCE-IT data show that VASCEPA/VAZKEPA (icosapent ethyl) ...

Home August 29, 2022
Home
A study from the Smidt Heart Institute and Cedars-Sinai's Division of Artificial Intelligence in Medicine shows that AI was more accurate in diagnosing cardiac function than sonographers. Illustration by Getty.
News | Artificial Intelligence
Late-Breaking Heart Research: AI More Accurate Than Technicians

August 29, 2022 — In a first-of-its-kind randomized clinical trial led by researchers at the Smidt Heart Institute and ...

Home August 29, 2022
Home
The USPSTF has issued a Recommendation Statement, relating to Statin Use for the Primary Prevention of Cardiovascular Disease in Adults
News | Cardiovascular Education
USPSTF Issues Statin Recommendation Statement

August 29, 2022 — ­The US Preventive Services Task Force (USPSTF) has issued a Recommendation Statement, relating to ...

Home August 29, 2022
Home
COVID mRNA vaccines are associated with a decreased risk of death in patients with heart failure, according to research presented at ESC Congress 2022.
News | Coronavirus (COVID-19)
COVID mRNA Vaccines are Safe in Patients with Heart Failure

August 26, 2022 — COVID mRNA vaccines are associated with a decreased risk of death in patients with heart failure ...

Home August 26, 2022
Home
A new Cedars-Sinai study is the first study proven to be effective at identifying coronary artery disease patients at highest risk for sudden cardiac death. Photo by Cedars-Sinai.
News | Sudden Cardiac Arrest
Genetic Score Detects Those at Risk for Sudden Cardiac Death

August 26, 2022 — Researchers in the Smidt Heart Institute at Cedars-Sinai are one step closer to identifying patients ...

Home August 26, 2022
Home
The Cardiovascular Research Foundation (CRF) and Fogarty Innovation announced today that the program is now available for the TCT MedTech Innovation Forum.
News | TCT
CRF and Fogarty Innovation Announce Agenda for TCT MedTech Innovation Forum

August 26, 2022 — The Cardiovascular Research Foundation (CRF) and Fogarty Innovation announced today that the program ...

Home August 26, 2022
Home
Jamshid Maddahi, MD, FASNC
News | PET Imaging
Late Breaking Flurpiridaz Trial Results at ASNC2022

August 25, 2022 — The results of “A Phase 3, Open-label, Multicenter Study of Flurpiridaz (F18) Injection for Positron ...

Home August 25, 2022
Home
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now